First patient used Cancer Vaccine and All tumors have been cleared!
- The synergistic effect of targeting T cells and NK cells
- Can we eat food from Japanese counties affacted by nuclear radiation?
- Unexpected mechanism of hallucinogenic drugs to reduce depression discovered
- Harvard: Prediagnostic Biomarkers of Smoking-Associated Lung Cancer
- First major breakthrough in the treatment of glioma in more than 20 years
- What is Tumor Bacterial Immunotherapy?
First patient used Cancer Vaccine and All tumors have been cleared!
First patient used Cancer Vaccine and All tumors have been cleared! United States has successfully developed a new anti-cancer vaccine! The first patient has announced: all tumors have been cleared!
Nowadays, cancer is a very common disease in humans, but earlier, it was a disease that rarely appeared in humans. Although there are drugs around the world to some extent, not all drugs are effective in treating all cancers.
Recently, a new cancer vaccine was successfully developed at the Mayo Clinic. In the first cancer patient who used the vaccine, all tumors have disappeared. Currently, the vaccine is in clinical trials.
Mayo Clinic successfully developed a new anti-cancer vaccine
Mayo Clinic doctors said that this vaccine can effectively eliminate cancer cells in the human body. Later, he revealed that in the process of clinical testing, it removed cancer cells from breast cancer patients. This lucky cancer patient, her name is Lee Mercker (Lee Mercker), lives in Florida. She is the first person in this clinical trial.
The first lucky subject’s tumor disappeared
When I heard in March that I had breast cancer, I was shocked because I am a fitness fanatic. The news was incredible to me and I had a healthy diet. After examination, the cancer is in the zero stage of DCIS, and the cancer cells have not spread, which means that the disease is in the early stage.
She faces three choices:
- Perform a tumor resection-remove cancer cells
- Mastectomy-removal of the breast
- Or participate in a clinical trial of a potentially life-saving vaccine to kill these cells and prevent their recurrence
Finally, Lee Mercker signed the document and chose to accept the 12-week clinical trial.
The blood was collected first, and a physical examination was carried out. After passing the test, the cancer vaccine was injected. Three consecutive injections with two arms rotation, a total of four times, two weeks apart.
It’s as simple as getting a flu shot
Dr. Chumri of the Mayo Clinic explained that vaccines fight cancer cells in the body. The vaccine can attack cancer by stimulating the patient’s own immune response, thereby completely eliminating those cancer cells. If we can train the immune system to recognize cancer cells or precancerous cells, then maybe the immune system can eliminate them even before they develop into cancer cells.
This vaccine has been successfully prepared and is available from stock, just like human influenza or pneumonia vaccines.
Mercker said that as part of the trial, she still underwent two mastectomy procedures to ensure that the breast cancer was completely separated from her body, and also to obtain tissues to prove the effectiveness of the cancer vaccine. The researchers studied the breasts she had removed. Tissue to obtain further results, the results confirmed that the cancer cells in Mercker’s body have been completely eliminated.
At present, two cancer patients are trying this cancer vaccine treatment, and now we are looking for more subjects, hoping that this vaccine can completely prevent cancer. Researchers at the Mayo Clinic revealed that this vaccine will be launched in phase I, II, and III clinical studies from 2020, and will be approved by the FDA within 8 years to be available to the public through hospitals and pharmacies.
What is a cancer vaccine?
Cancer vaccine is one of the latest treatment methods in cancer immunotherapy, because it can identify the proteins present on specific cancer cells, can prevent the growth of cancer cells, prevent cancer recurrence, and remove residual cancer cells after treatment.
Compared with chemotherapy and radiotherapy, cancer vaccines usually do not produce serious side effects. Unlike chemotherapy and radiotherapy that directly kill tumor cells and normal rapidly dividing cells in the body, cancer vaccines and other immunotherapies exert their effects by stimulating the body’s immune system. The anti-cancer effect is only for tumor cells, reducing the occurrence of side effects.
In view of these characteristics, cancer vaccines provide cancer patients with a more targeted and gentler method of cancer treatment, which is much less harmful to the body, and patients are hopeful of a better quality of life.
Classification of cancer vaccines
Currently, there are two types of cancer vaccines on the market. One is a preventive vaccine, such as HPV cervical cancer vaccine.
The other is a therapeutic vaccine, such as Provenge (sipuleucel-T), which is the world’s first and only cancer vaccine approved by the US FDA to treat metastatic prostate cancer. Clinical studies have found that the drug prolongs the average survival time of patients For at least 4 months, this opened a new era of cancer immunotherapy.
In addition, Cuba has approved two lung cancer vaccines, namely the first-generation vaccine CIMAvax-EGFR and the second-generation vaccine Vaxira; the Japanese fusion cell vaccine has also been approved by the Ministry of Health, Labour and Welfare for the treatment of various solid tumors; Japan’s Ministry of Health, Labour and Welfare official Announced that DC immunotherapy is included in the A-level advanced medical technology, and has been used in the clinical treatment of tens of thousands of advanced cancer diseases; the German government-approved DC cell preparation laboratory has used DC immunotherapy to treat thousands of patients. (Introduced one by one later)
However, due to various reasons and limitations, these vaccines have not been widely used all over the world.
With the continuous advancement of science and technology, a variety of cancer vaccines have gradually entered the clinic. According to different technical principles, cancer vaccines can be divided into:
- Dendritic cell (DC) cancer vaccine
- Recombinant cancer vaccine
- Antigen/Adjuvant Cancer Vaccine
- Whole cell cancer vaccine
- Viral vectors and DNA cancer vaccines
Below, the editor will take a look at cancer vaccines that are currently more mature in technology and have made significant progress. (Get more treatment information through 400-626-9916)
Cuban Lung Cancer Vaccine
The idea of a lung cancer vaccine sounds absurd. After all, lung cancer is not the flu. However, 25 years of research by Cuban researchers have made this therapeutic lung cancer vaccine now a reality! Early trials have shown that this treatment can help patients with advanced lung cancer under the age of 60 extend an average of 11 months longer than unvaccinated patients!
The non-small cell lung cancer vaccine CIMAvax has undergone a large number of clinical trials in Cuba and other countries, but the purpose of the trial in the United States is to determine whether the vaccine combined with PD-1 is more effective and whether it can accelerate the immune system’s response. This is the first attempt. Combination therapy.
The PD-1 inhibitor nivolumab is currently one of the most researched anti-cancer drugs in the world. It is an antibody that can trigger autoimmunity against cancer. It has become the standard treatment for patients with non-small cell lung cancer in the United States. Listed and sold in China.
In January 2018, the first group of patients with advanced lung cancer who had undergone initial treatment in the United States began treatment with CIMAvax vaccine combined with PD-1 (Opdivo, nivolumab). Researcher Pedro Camilo Rodríguez said that this is a very innovative method, for us, the vaccine is a breakthrough achievement.
The world’s first registered vaccine for advanced non-small cell lung cancer-CimaVax
Recently, the director of the Thoracic Oncology Department of Roswell Park Comprehensive Cancer Center and principal investigator Grace Dy, MD, announced that based on the positive results of the first part of the Phase 1/Phase 2 trial, the lung cancer vaccine CIMAvax-EGF has entered the second phase of clinical trials. To study the survival benefits of this combination method as a maintenance treatment for patients with advanced lung cancer.
But note that CimaVax EGF cannot prevent the development of cancer, let alone cure cancer. Instead, it initiates a mechanism by which the uncontrolled growth and division of cancer cells is more restricted, thereby turning advanced aggressive lung cancer into a chronic disease. At present, the Cuban lung cancer vaccine has been approved in more than 80 countries around the world, and domestic patients can also apply to purchase the vaccine from overseas (400-626-9916).
Dendritic cell vaccine for all solid tumors
In the human blood system, there is an immune cell that plays a vital role in the human immune system, namely dendritic cells (dendritic cells, also known as DC cells), accounting for 1% of the total immune cells. DC cells are the most powerful antigen-presenting cells in the human body.
If there are no DC cells in the immune system that carry antigens to obtain T cells, the immune cells cannot find foreign objects (viruses, bacteria, cancer cells) that invade the human body by themselves, and the human body’s immune function Will be greatly reduced.
The antigen presentation of DC cells is at the center of the immune system. It can not only educate naive T cells to become antigen-specific cytotoxic T cells (CTL) through antigen presentation, but also interact with other immune cells in the body such as NK cells and NKT. Cells and B cells interact to activate the immune system, recognize and kill tumors.
How dendritic cells work
As a key antigen presenting cell, DC cells are mainly used to recognize and swallow tumor or viral antigens, and then transfer the antigens to the surface of DC cell membranes after processing. Subsequently, the DC cells carrying the antigen information are contacted with the naive T cells, and the antigen information is transmitted to the T cells, which stimulates the activation and expansion of the T cells, and produces a large number of T cells that specifically recognize tumor cells or virus-infected cells. T cells are the main force of cellular immunity, accounting for 58% of immune cells.
Dendritic vaccine clinical trial
Many therapeutic vaccination approaches against cancer are being carried out in the clinic. Search for the term dendritic cell vaccine on the official international clinical trial website clinicaltrials.gov, and there are 54 clinical studies. A common feature in these studies is that the key step of vaccination is the effective presentation of cancer antigens to T cells.
Because DC is the most effective antigen-presenting cell, it is possible to use their diversity to produce improved therapeutic vaccines. Learn more about DC vaccines or participate in clinical trials through 400-626-9916.
Dendritic vaccine has been widely recognized internationally
The US FDA approved the first anti-cancer vaccine Provenge (sipuleucel-T) as a DC vaccine for the treatment of metastatic prostate cancer; Japan’s Ministry of Health, Labour and Welfare officially announced that DC immunotherapy has been included in Class A advanced medical technology, and has been used in tens of thousands of advanced cases Clinical treatment of cancer diseases; The DC cell preparation laboratory approved by the German government has used DC immunotherapy to treat thousands of patients.
Therefore, the DC vaccine has been widely recognized by the international medical anti-tumor field and has been used in clinical treatment. This is a new hope for the treatment of cancer patients and a new way to cure cancer.
Fusion cell vaccine for all solid tumors
We know that when the immune system cleans up tumor cells, cytotoxic T cells (CTL) are responsible for attacking cancer cells, and dendritic cells (DC) are responsible for presenting antigenic information to CTL cancer cells. The two cooperate with each other and cooperate closely to complete the process. The great cause of killing tumors. The DC cell is equivalent to the signal soldier, passing the searched cancer information to the assistant unit (CTL cell), and the CTL unit kills the cancer cell based on the information.
The fusion cell vaccine is an improvement on the current DC-CTL therapy, and now it can make a variety of cancer antigens carried by cancer cells become the target of the immune system, with stronger specificity. The improved fusion cell therapy is able to send all tumor cell antigens to CTL. The technical principle is this.
Principles of Fusion Cell Vaccine Therapy
The modified DC-CTL therapy is to extract cancer cell antigens in vitro (not all cancer antigens, only some conventional antigens), and then use the antigen to stimulate the DC cells induced in vitro to carry antigenic information for presentation Give CTL cells the ability to recognize cancer cells and then kill them. However, the antigen information obtained by DC cells is relatively limited, which will make some cancer cells unable to be identified.
The improved fusion cell technology is to fuse the entire cancer cell with the DC cell, and all cancer antigen information is presented to the DC cell. The resulting fusion cell has the antigenicity of cancer cells,
It also has the presentation function of DC cells. Therefore, the fused cells can carry all kinds of cancer antigens to find CTL cells, “telling that cancer cells are like this,” so that they have the ability to recognize and kill cancer cells.
New virus vector and DNA cancer vaccine
A couple of scientists in the United States have developed a new type of cancer vaccine called ImmuneFx (IFx). It is not a preventive vaccine that protects the human body from rapid mutations in cancer cells, but a combination of gene and cell therapy. “Therapeutic” vaccines.
The “ImmuneFx” therapeutic vaccine designed by the couple of scientists is directly injected into the tumor, thereby forcing cancer cells to express specific bacterial antigens on their surface. The immune system can easily recognize this bacterial antigen, allowing T cells to effectively attack the tumor. cell. In other words, after the vaccine is injected, the body’s immune system is activated, causing it to destroy tumor cells throughout the body without harming healthy cells and tissues.
High-tech: the use of genetic engineering technology to prepare plasmid DNA vaccines
The treatment principle of ImmuneFx vaccine is to prepare a plasmid DNA vaccine (Streptococcus pyogenes emm55 gene (pAc / emm55)) in vitro through genetic engineering technology. The plasmid DNA in the tumor cells of vaccine patients has a feature that can be used in The gene carried by the host cell (tumor cell) is expressed, emm55 is a serotyping antigen of Streptococcus pyogenes, which means that a bacterial antigen can be expressed in tumor cells, tumor cells are therefore marked, and the immune system responds to this Bacterial antigens are particularly sensitive and can quickly recognize and mobilize the body’s immune cells to kill.
Fifty years ago, the development of vaccines against measles, mumps and rubella saved many lives.
More and more new vaccines have entered the stage of clinical trials. In subsequent trials, individualized vaccines will be used for various types of cancer, and having a sufficient number of new antigen vaccines has great potential.
In addition, a large number of studies have confirmed the feasibility of cancer vaccines. I believe that as more clinical research experiments are followed up in the future, cancer vaccines will play an important role in cancer treatment. Just one shot from our dream of letting tumors go. It’s getting closer and closer.
(source:internet, reference only)
Disclaimer of medicaltrend.org